Stephens Begins Coverage on OptimizeRx (NASDAQ:OPRX)

Stephens began coverage on shares of OptimizeRx (NASDAQ:OPRX) in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage issued an equal weight rating and a $5.50 price objective on the stock.

OPRX has been the subject of a number of other reports. Royal Bank of Canada lowered their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. JMP Securities cut their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday, November 14th. Roth Mkm reiterated a “buy” rating and issued a $16.00 price objective (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Finally, Stifel Nicolaus dropped their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.71.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $4.91 on Friday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a fifty day simple moving average of $5.41 and a 200 day simple moving average of $7.87. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65. The company has a market cap of $90.45 million, a P/E ratio of -3.69 and a beta of 1.34.

Insider Transactions at OptimizeRx

In related news, CEO William J. Febbo acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. This trade represents a 3.44 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds and other institutional investors have recently modified their holdings of OPRX. BNP Paribas Financial Markets raised its position in shares of OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after buying an additional 2,414 shares in the last quarter. Connors Investor Services Inc. boosted its position in shares of OptimizeRx by 15.1% during the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after acquiring an additional 2,500 shares during the last quarter. Summit Securities Group LLC purchased a new position in shares of OptimizeRx during the second quarter worth about $25,000. Rhumbline Advisers raised its stake in OptimizeRx by 9.2% in the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after purchasing an additional 2,658 shares in the last quarter. Finally, Greenwood Capital Associates LLC lifted its position in OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after purchasing an additional 4,999 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.